In combination w/ irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy for adults w/ metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin-containing regimen.
Discontinue in case of severe hypersensitivity reactions. Do not administer as IV push or bolus. Increased risk of haemorrhage. Risk of GI perforation; fistula formation; cardiac failure & ejection fraction decreased; thomboembolic events; severe proteinuria, nephrotic syndrome, thrombotic microangiopathy. Increased risk of grade 3-4 HTN. May promote formation of aneurysms &/or artery dissections. Higher incidence of neutropenic complications & severe diarrhoea. Potential for compromised wound healing. Suspend treatment at least 4 wk prior to elective surgery. Reports of osteonecrosis of the jaw & posterior reversible encephalopathy syndrome. Patients w/ ECOG performance status ≥2 or having significant co-morbidities; severe hepatic &/or renal impairment. Male & female fertility are likely to be compromised during treatment. Women of childbearing potential & fertile males should use effective contraception during & up to a min of 6 mth after the last dose of treatment. Pregnancy & lactation. Elderly ≥65 yr.
Sign Out
